Turn Therapeutics appoints Martin Dewhurst to its Board of Directors

Turn Therapeutics Inc.

Board expanded from 5 to 6 members; Dewhurst appointed as independent Class III director effective Jan 7, 2026.
Over 30 years life sciences experience; former McKinsey senior partner and co-leader of global life sciences practice.
Received initial RSU grant with $100,000 fair value, vesting at one year or change of control.
Will chair compensation committee; eligible for annual $70,000 RSU grant after first anniversary of direct listing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.